Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 3/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.37 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.37 |
| ▸ | GPR52 | Q9Y2T5 | 2/20 | 0.37 |
| ▸ | UBE2M | P61081 | 3/20 | 0.36 |
| ▸ | DCUN1D1 | Q96GG9 | 3/20 | 0.36 |
| ▸ | DRD4 | P21917 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5246034 | 0.80 | GPR142 (0.46) | UBE2MDCUN1D1MAPTTHRBGPR142 | |
| SCHEMBL325035 | 0.80 | ALDH1A1 (0.40) | MAPTKMT2A | |
| SCHEMBL5246039 | 0.73 | GPR142 (0.44) | UBE2MDCUN1D1MAPTTHRBGPR142 | |
| SCHEMBL2582295 | 0.69 | GAA (0.42) | KMT2A | |
| SCHEMBL2581672 | 0.68 | DRD4 (0.53) | SIGMAR1DRD4 | |
| SCHEMBL4261853 | 0.66 | LMNA (0.48) | MAPTTHRB | |
| SCHEMBL2582296 | 0.65 | CRHBP (0.44) | OPRM1MAPTTHRBKMT2A | |
| SCHEMBL1944694 | 0.64 | DRD4 (0.44) | SIGMAR1SMYD3GPR52UBE2MDCUN1D1 | |
| SCHEMBL2585658 | 0.63 | CCR2 (0.46) | SMYD3DRD4 | |
| SCHEMBL315901 | 0.63 | ALDH1A1 (0.52) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8093272-B2 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2012-01-10 | — | — | US | claimed |
| US-8093272-B2 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | GRUENENTHAL GMBH (DE) | 2007-06-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129369-A1 | Heteroaryl substituted cyclohexyl-1,4-diamine compounds | DDC, DPYD, PKD1 | OPRM1 2315/4885TRPV1 4251/4885SIGMAR1 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.